Chinanews.com, Shanghai News, April 23 (Liu Yifei Yu Jun) Shanghai's urban customized commercial supplementary medical insurance - "Shanghai Huibao 2024 Edition" was officially launched on the 23rd, and insured users only need to pay 129 yuan this year to enjoy a total insurance amount of up to 3.1 million yuan. China's first CAR-T cell therapy product, Yikaida ® (Axileucel Injection), has been included in the "Shanghai Huibao" for the third year this year, and due to the trust and official recognition of the public, the new phase of the protection liability has added its second-line indication approved in June 2023, which is expected to further reduce the treatment burden of lymphoma patients and help more patients embark on the road of accessibility and cure.
Chen Xingrong, Chief Executive Officer (CEO) of Fosun Kite, said: "As a pioneer in China's CAR-T track, Fosun Kite has always adhered to the unmet clinical needs and strived to promote CAR-T cell therapy products to benefit more patients, so that patients can 'use medicine' and make medicine more 'affordable'. Yikaida ® has been included in the 'Shanghai Huibao' for three consecutive years, which fully reflects the support and attention of the government and the public to improve the level of medical security and the treatment of lymphoma diseases. We would like to express our sincere gratitude to the Shanghai Municipal Health Insurance Bureau and other government departments and the members of the 'Shanghai Huibao' co-insurance body for their ® recognition and attention, as well as the team of expert doctors who have made unremitting efforts for the clinical treatment of lymphoma. We will do our best to enable more patients to benefit from innovative medicines. ”
Yikaida ® has been included in the "Shanghai Huibao" for 3 consecutive years, helping to heal it
In recent years, due to the aging of the population, the number of lymphoma patients in Shanghai has increased year by year, and it was once considered an incurable disease by the public. It was not until the advent of CAR-T therapy that the public had a new understanding of lymphoma treatment, and lymphoma patients also gained hope for a cure. With its excellent real-world efficacy and safe and reliable clinical performance, Yikaida ® has been included in the "Shanghai Huibao" for three consecutive years, which is expected to further alleviate the medical burden of lymphoma patients in Shanghai.
Axicabtagene Ciloleucel (Axi-cel) is the CAR-T product with the largest and largest sample size of real-world study data in the world, and the CAR-T product with the longest follow-up time available. In a post-hoc analysis of the ZUMA-1 study, the 5-year lymphoma-related event-free survival (LREFS) rate confirmed the potential for Axi-cel to cure patients with refractory LBCL. The ZUMA-7 study was used in the second-line treatment of relapsed and refractory LBCL (R/R LBCL), which demonstrated excellent efficacy across the board of Axi-cel, doubling the best complete response (CR) rate to 65%, extending median event-free survival (EFS) by nearly 45% (10.8 months vs. 2.3 months), and achieving a median overall survival (OS) with a median follow-up of 47.2 months, and a positive result for median overall survival (OS) compared with second-line standard of care (SOC) (NR vs 31.1 months) , the risk of death was reduced by 27% (HR0.73, P=0.03), which is currently the only CAR-T cell therapy product to achieve a positive result of OS in the second-line treatment.
Up to now, as the first approved CAR-T therapy drug in China, Yikaida ® has treated more than 600 patients with relapsed/refractory large B-cell lymphoma. Fosun Kite has established more than ® 160 high-standard treatment centers in 26 provinces, autonomous regions and municipalities across the country, and promoted the inclusion of more ® than 100 urban Huimin Insurance projects and more than 75 commercial health insurance programs, so that innovative cell therapy therapies can further benefit more patients and help them regain hope for survival. In the past two years, nearly 60 patients have benefited from the ® "Shanghai Huibao". According to past cases, after receiving CAR-T ®treatment, the insured patients can receive up to 42% of the drug expenses covered by "Shanghai Huibao", and the compensation amount can reach 500,000 yuan.
As an urban customized commercial supplementary medical insurance under the guidance of the Shanghai Municipal Medical Security Bureau and supervised by the Shanghai Supervision Bureau of the State Administration of Financial Supervision and Administration, "Shanghai Huibao" provides a reassuring, worry-free and reassuring protection platform for the treatment and rehabilitation of patients with critical illnesses with inclusive insurance prices, comprehensive liability protection and convenient claims services.
For the first time, second-line indications were included in the "Shanghai Huibao", and the scope of inclusiveness was further expanded
With the continuous optimization of "Shanghai Huibao", more and more new drugs and special drugs and more indications have been included in this insurance. In particular, the inclusion of cutting-edge bio-innovative drugs such as Yikaida ® not only benefits patients, reduces the medical burden of the insured, and allows ordinary citizens to enjoy the achievements of biomedical science and technology innovation, but also encourages cutting-edge medical technology and scientific and technological innovation in the pharmaceutical industry.
On the 13th of this month, the "Shanghai Huibao" co-insurance body issued the "Shanghai Huibao 2023 Version" product upgrade and supplementary compensation announcement, which expanded the newly approved second-line indication of Yikaida ®, that is, adult large B-cell lymphoma (LBCL) that is ineffective or relapsed within 12 months after first-line immunochemotherapy, in the protection liability of CAR-T treatment drug cost insurance, and retrospectively claims to the time of indication marketing. The "Shanghai Huibao 2024 Edition" directly includes the second-line indications of Yikaida ® in the scope of protection during the sale stage.
Adult large B-cell lymphoma (LBCL) is a common malignant lymphoma, accounting for about 30-40% of non-Hodgkin lymphoma, with few treatment options, rapid disease progression, high mortality and short survival, and the incidence in China has shown a rapid growth trend in recent years. Traditional radiological, chemical, immunological and other treatment methods make patients face many difficulties in the treatment process, such as poor treatment effect, recurrent disease, etc., and there is an urgent need for high-value innovative drugs.
In June 2023, Yikaida ® was approved for marketing for the second-line indication. The study data showed that CAR-T therapy with Yikaida ® could significantly improve the survival of patients with relapsed and refractory lymphoma compared with traditional treatment, with a 4-year survival rate of 54.6%. The approval of the second-line indication of Yikaida ® has successfully advanced the treatment of adult large B-cell lymphoma and brought hope to more patients who have failed or relapsed with first-line immunochemotherapy.
Yikaida ® has been included in the "Shanghai Huibao" for three consecutive years, and has been newly included in the second-line indications, which is one of the blockbuster insurance drugs upgraded and launched in the "Shanghai Huibao 2024 Version". This is inseparable from the excellent clinical performance of Yikaida ®, and also inseparable from the unremitting efforts made by the Shanghai Municipal Government to promote the development of the biomedical industry and the health protection of the people. Fosun Kite will further focus on unmet clinical needs, so that scientific and technological innovation achievements can truly benefit more patients. Yikaida ® will continue to help "Shanghai Huibao" to provide more health protection for patients and promote the fair and inclusive development of the medical industry. (ENDS)
Editor: Yu Jun